Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B
HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.
You may also be interested in...
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
The HHS Office of Inspector General finds Medicare Part B could have saved $3.1 billion on 60 of the costliest drugs by applying Medicaid-level rebates, which the office says “warrants further deliberation.” But noting Part B drug rebates are not actively under consideration by the administration or Congress, CMS says it will not devote resources to examining the issue.
Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.